Low-Dose Bevacizumab Maintains Efficacy With Reduced Adverse Events in Liver Cancer - PubMed
3 hours ago
- #hepatocellular carcinoma
- #treatment tolerability
- #bevacizumab dosing
- A retrospective study compared low-dose (5-7.5 mg/kg) and standard-dose (15 mg/kg) bevacizumab combined with atezolizumab in 307 patients with unresectable hepatocellular carcinoma (uHCC).
- After propensity score matching (122 patients per group), efficacy outcomes including objective response rate, disease control rate, progression-free survival, and overall survival were similar between the two dose groups.
- Low-dose bevacizumab significantly reduced the incidence of low-grade adverse events such as proteinuria, rash, thrombocytopenia, and gastrointestinal bleeding compared to the standard dose.
- The findings suggest that a low-dose bevacizumab strategy maintains antitumor efficacy while improving tolerability, potentially reducing treatment-related side effects and costs.
- Long-term follow-up is needed to confirm that the comparable efficacy persists over time.